Multinational firms unveil China strategies and investments at CIIE

Since establishing its presence in Shanghai's Pudong New Area in 1994, Roche Pharma China has been dedicated to building and continuously upgrading a comprehensive pharmaceutical value chain encompassing early-stage research, drug development, production, marketing and open collaboration.

At the CIIE, Roche showcased its complete industry chain layout for the first time. The display included the company's Shanghai headquarters, the Roche China accelerator, and a panoramic view of the new biopharmaceutical production facility, which represents an investment of 2.04 billion yuan ($286 million) and was announced in May.

"This facility is the first of its kind among multinational pharmaceutical companies to achieve localized production of large-molecule antibody biologics in China, underscoring Roche's long-term confidence in the China market. As Roche approaches its 100th anniversary in China next year, the company plans to continue increasing its investment," said Bian Xin, CEO of Roche Pharma China.

Aiming to export Chinese medical standards and innovation capabilities, Fosun Health announced a collaboration between Guangzhou Fosun Chancheng Hospital and the Guangzhou Belt and Road Healthcare Center to jointly establish a medical service center in Bangladesh.

Fosun Health has been actively advancing such medical projects in countries and regions involved in the Belt and Road Initiative, including Bangladesh and Indonesia. Through the construction of overseas hospitals, joint labs and health management centers, it aspires to contribute Chinese expertise to healthcare development in those countries and regions.